This version of the guidance has been updated to reflect several important developments, including the recent approvals of glecaprevir/pibrentasvir and sofosbuvir/velpatasvir/voxilaprevir. Updated recommendations reflecting these approvals are provided throughout the guidance.
In addition to updates to all the sections, the following new sections have been added to the guidance:
Updated references have been provided throughout the guidance.